Zimmer Biomet
918 hedge funds and large institutions have $19.6B invested in Zimmer Biomet in 2022 Q3 according to their latest regulatory filings, with 58 funds opening new positions, 288 increasing their positions, 354 reducing their positions, and 89 closing their positions.
129% more call options, than puts
Call options by funds: $81.4M | Put options by funds: $35.5M
17% more funds holding in top 10
Funds holding in top 10: 12 → 14 (+2)
0.2% less ownership
Funds ownership: 89.68% → 89.48% (-0.2%)
1% less capital invested
Capital invested by funds: $19.7B → $19.6B (-$109M)
4% less funds holding
Funds holding: 957 → 918 (-39)
19% less repeat investments, than reductions
Existing positions increased: 288 | Existing positions reduced: 354
35% less first-time investments, than exits
New positions opened: 58 | Existing positions closed: 89
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$237M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$178M |
| 3 |
Millennium Management
New York
|
+$116M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$115M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$85.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$368M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$165M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$101M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$63.1M |
| 5 |
NI
Nuance Investments
Kansas City,
Missouri
|
-$46.5M |
ZBH Hedge Fund Activity: Q3 2022 in Review
918 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Zimmer Biomet (ZBH) for Q3 2022, worth a combined $19.6B — down 0.55% from $19.7B a quarter earlier.
Sellers outnumbered buyers: 89 funds closed out of ZBH and 58 opened new positions — a net loss of 31 holders — while 354 trimmed existing stakes and 288 added.
The largest buyer was Citadel Advisors, adding an estimated $237M. The largest seller was JP Morgan Chase, cutting an estimated $368M.
- 918 institutional investors held Zimmer Biomet (ZBH) as of Q3 2022, down from 957 in Q2 2022.
- Funds reported $19.6B of Zimmer Biomet stock for Q3 2022, down 0.55% quarter-over-quarter.
- 58 funds opened new Zimmer Biomet positions in Q3 2022 and 89 closed out, a net change of -31 holders.
- The largest Zimmer Biomet buyer in Q3 2022 was Citadel Advisors, an estimated $237M added.
- The largest Zimmer Biomet seller in Q3 2022 was JP Morgan Chase, an estimated $368M sold.
Based on aggregated 13F filings for Q3 2022.